Objective: The present study aims to describe the efficacy and safety of onabotulinum toxin A (BonT-A) with evaluation of treatment satisfaction and impact on quality of life in chronic migraine (CM) patients in real life. Methods: This study was conducted in CM patients who were treated with BoNT-A with 12 months of follow-up. Data about outcome, adverse events, and patients’ pre- and post-treatment status including health-related quality of life data were analyzed. Health-related quality of life scores were measured at baseline and months 6 and 12 after the beginning of BoNT-A administration. Results: Of 42 enrolled patients, 30 were included in the analysis. At 12 months, all patients showed a reduction in number of headaches and analgesic use per month and none reported adverse events. After BoNT-A supplementation, health-related quality-of-life scores improved significantly. There was a direct association between health-related quality of life with reduction of headache days at the end of study. Conclusion: This study confirms that BoNT-A treatment is effective on CM and improves the functional well-being and quality of life of patients.

中文翻译：

---

用肉毒杆菌毒素 A 治疗的慢性偏头痛患者的有效性、安全性和与健康相关的生活质量

目的：本研究旨在描述肉毒杆菌毒素 A (BonT-A) 的疗效和安全性，并评估现实生活中慢性偏头痛 (CM) 患者的治疗满意度和对生活质量的影响。方法：本研究在接受 BoNT-A 治疗的 CM 患者中进行，随访 12 个月。分析了关于结果、不良事件和患者治疗前后状态的数据，包括与健康相关的生活质量数据。与健康相关的生活质量评分在基线和 BoNT-A 给药开始后的第 6 个月和第 12 个月进行测量。结果：在 42 名登记患者中，30 名被纳入分析。在 12 个月时，所有患者的头痛次数和每月使用镇痛药的次数都有所减少，并且没有人报告不良事件。补充 BoNT-A 后，与健康相关的生活质量得分显着提高。研究结束时，健康相关的生活质量与头痛天数的减少之间存在直接关联。结论：本研究证实 BoNT-A 治疗对 CM 有效，并改善患者的功能健康和生活质量。